Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TriSalus Life SciencesTLSI -1.31%22 3-Year EPS without NRI Growth Rate is 78.00% as of Jun. 2026, which is 4% above its 10-year median of 75.30. GuruFocus rates TLSI with a GF Score™ of 22/100 and a GF Value™ of $3.77 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 658 Medical Devices & Instruments companies, TriSalus Life Sciences ranks better than 96.2% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 78.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 5 years, the highest 3-Year average EPS without NRI Growth Rate of TriSalus Life Sciences was 78.00% per year. The lowest was 72.60% per year. And the median was 75.30% per year.
TriSalus Life Sciences (NAS:TLSI) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
TriSalus Life Sciences 3-Year EPS without NRI Growth Rate Related Terms
TLSI vs TMCI, SENS, SGHT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's 3-Year EPS without NRI Growth Rate falls into.
TriSalus Life Sciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 78.00% mean?
TriSalus Life Sciences (TLSI) has a 3-Year EPS without NRI Growth Rate of 78.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for TriSalus Life Sciences and its competitors. This is near median its historical median of 75.30. Over the past decade, TriSalus Life Sciences' 3-Year EPS without NRI Growth Rate has ranged from 72.60 to 78.00. According to the industry distribution chart, TriSalus Life Sciences ranks #25 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 3.8%.
Is TriSalus Life Sciences' 3-Year EPS without NRI Growth Rate too high?
TriSalus Life Sciences' current 3-Year EPS without NRI Growth Rate of 78.00% is near median its 10-year median of 75.30. Over the past 10 years, this metric has ranged from a low of 72.60 to a high of 78.00. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. TriSalus Life Sciences' value of 78.00% is 868.9% above this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #25 out of 658 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' 3-Year EPS without NRI Growth Rate compare to TMCI and SENS?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #25 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places TriSalus Life Sciences in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. TriSalus Life Sciences' value of 78.00% is 868.9% above this benchmark. Historically, TriSalus Life Sciences' own 3-Year EPS without NRI Growth Rate has ranged from 72.60 to 78.00 over the past decade. While the company's 10-year median is 75.30 vs. the industry median of 8.05, TriSalus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current 3-Year EPS without NRI Growth Rate of 78.00% is 868.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current 3-Year EPS without NRI Growth Rate is 78.00%, which is near median its own 10-year median of 75.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.77, compared to a current price of $5.64 — trading 49.6% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 78.00%, which is near median its 10-year median of 75.30 and 868.9% above the Medical Devices & Instruments industry median of 8.05. TriSalus Life Sciences' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current 3-Year EPS without NRI Growth Rate is 78.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $5.64 is trading 49.6% above its estimated GF Value™ of $3.77.
GuruFocus considers TriSalus Life Sciences to be Significantly Overvalued.
Key valuation signals for TLSI:
3-Year EPS without NRI Growth Rate: 78.00% (near median its 10-year median of 75.30)
GF Value™: $3.77 vs. price of $5.64 (49.6% above fair value)
Industry Position: 868.9% above the Medical Devices & Instruments median (#25 of 658)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
22GF Score
Get the complete analysis for TLSI
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
